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INTRODUCTION AND OBJECTIVES: The following multi-
center randomized protocol aimed to evaluate the efficacy and tolera-
bility of the combination therapy between SeR, Ly and Se (Profluss ) +
tamsulosin versus monotherapies with Ser, Ly and Se (Profluss ) or
tamsulosin in patients with LUTS / BPH.
METHODS: FromMarch 2011 to March 2012, 225 patients from
11 Italian centers were enrolled in this randomized, double-blind study.
The inclusioncriteriawere: agebetween55and80yearsold, absence
prostate cancer, PSA<4 ng/ml, IPSS12, prostate volume 60 cc, peak
flow 15 ml/s, post -void residual (PVR)<150 ml. The participants were
randomized with a 1:1:1 ratio into 3 treatment arms each consisting of
75 patients: group A (Profluss  1 tablet per day for 1 year), group B
(tamsulosin 0.4 mg 1 tablet a day for 1 year) and group C ( Profluss  1
tablet per day for 1 year + tamsulosin 0.4 mg 1 tablet per day for 1 year).
RESULTS: Of all patients, 219 patients completed 12 months of
treatment. The treatment groups were statistically balanced. At the
intergroup analysis, significant differences were found between group C
and group A in terms of IPSS (median change: -2, p<0.01), IPSS%
(median change: -9.3, p<0.01), peak-flow (median change: 1, p¼ 0.04),
peak-flow% (median change: 10.5, p¼ 0.02) and PVR (median change:
-20.0, p¼0.001). We demonstrated a significant increase of at least 3
points in the IPSS in 71.6 % of subjects in group C when compared to
group A ( 53.7 %, p¼ 0.01) and group B (51.3 %, p¼ 0.04), a significant
decrease of 25%of the IPSS in 44.6%of patients in groupC compared to
group A ( 23.9 %, p ¼ 0.004) and group B (23.1 %, p ¼ 0.002) and
a significant increase of 30 % of peak-flow in 47.30 % of patients of
Group C compared to group A (29.85%, p¼0.03) and group B (30.77%,
p¼0.03). Significant differences were found in terms of IPSS (median
change: -2.0, p¼ 0.002), IPSS% (median change: -9.0, p¼0.008), peak-
flow (median change: 0.8, p¼0.04) and peak-flow% (median change:
6.4, p¼0.02) between group C and group B.
No difference between the two groups in terms of PVR (p¼0.23).
CONCLUSIONS: In this multicenter, randomized, double-blind
study the combination therapy with Ser-Se-Ly + tamsulosin 0.4 mg for 1
year was demonstrated to be more effective than the individual mono-
therapies in terms of reduction of the symptom score (IPSS) and in
terms of increasing the Qmax in patients suffering from LUTS / BPH of
moderate to severe
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INTRODUCTION AND OBJECTIVES: We conducted an
objective (stereological) histological analysis of the stromal components
of the transition zone of benign prostatic hyperplasia (BPH) patients
using or not using a combination of tamsulin (0.4-mg) and dutasteride
(5-mg).METHODS: BPH samples were analyzed in the transition zone
of 5 patients submitted to open surgery without previous treatment
(control group) and 5 patients with BPH, submitted to open surgery,
which underwent treatment with tamsulosin + dutasteride for 3 months
prior to surgery.
The samples were removed after open surgery, and fixed in 4%
buffered formalin for a maximum period of 24 hours. Fragments from
the 2 groups were subjected to the following histochemical techniques;
hematoxylin-eosin, Masson’s trichrome and Picrosirius red for anal-
ysis of connective tissue, and immunohistochemical staining by using
the anti-alpha-actin for the analysis of smooth muscle fibers and anti-
elastin for analysis elastic system. Quantitative analysis was per-
formed using Image J software with the differentiation method of color
segmentation.
RESULTS: The analysis of sections stained by Picrosirius
observed under polarized light showed no difference in collagen
arrangement and distribution between treated and untreated patients.
Both groups presented reddish homogeneous fibers in all analyzed
fields, characterizing the presence of thicker fibers, possibly collagen
type I. In the sections stained by Masson’s trichrome, the quantitative
analysis showed a significant decrease of approximately 34% of the
collagen in individuals that used combo dart, when compared to con-
trols. The immunohistochemical analysis showed an increase of 42% in
the elastic system fibers in patients using combodart, when compared
to controls. Regarding smooth muscle fibers, the patients in combodart
group presented an increase of 81%.
CONCLUSIONS: Although these results are preliminary, with a
small number of patients, to our knowledge, this is the first report of a
comparative objective of BPH stromal components of controls and
patients using combodart. The study would continue increasing the
number of patients and an analysis of other components of the stroma
and parenchyma.
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INTRODUCTION AND OBJECTIVES: To compare the efficacy
and safety of alfuzosin alone, flurbiprofen alone, and alfuzosin plus
flurbiprofen combination for lower urinary tract symptoms (LUTS)
caused by benign prostatic obstruction (BPO).
METHODS: Seventy-eight patients complaining of LUTS sec-
ondary to BPO were enrolled in this clinical trial. Patients without any
cardiac or hepatorenal insuffenciency and without peptic ulcus history
were randomly assigned to receive alfuzosin XL 10 mg, flurbiprofen SR
200mg or combination treatment. Trans-rectal ultrasound was per-
formed for measurement of prostatic volume firstly, then patients were
evaluated by using International Prostate Symptom Score (IPSS)
(irritative, obstructive and total separately), uroflowmetry (maximal and
average urinary flow rate (Qmax and Qave)) and both at baseline and
following a 4-week treatment course.
RESULTS: There was not any difference among the groups
regarding age and baseline values of prostate volume, irritative,
obstructive and total IPSS, Qmax, Qave and residue (P>.05). The total,
irritative and obstructive IPSS and residue decreased significantly in all
3 groups after treatment (P <.01). Qmax and Qave significantly
improved only in combination therapy group (P <.01) without any
additional significant side effect.
CONCLUSIONS: A combination of an alpha blocker alfuzosin
with flurbiprofen which is a member of the phenylalkanoic acid
